Do you have news you would like to share on the NIVAS News Hub?
If you have an RSS feed you wish to share with up please contact us here.
Showing 61-72 of 553 results.
"Virtual visits demonstrate noninferiority to in-person visits based on the incidence of catheter complications and readmission rates. New evaluation techniques need to be developed for this high-risk populations in virtual visits to establish effective and safe patient management” Munroe et al (2025).
"Genta-EDTA-Na2 used as intra-catheter locks may be a promising anti-biofilm candidate to be studied in a randomized controlled trial” Lebeaux et al (2025).
"Tigecycline meets the UK YCD criteria of ≤5% degradation limit, indicating its suitability for both intermittent and continuous 24-h infusion in OPAT programs” Wolie et al (2025).
"We conclude that S-OPAT is a viable model of care, demonstrating favourable clinical outcomes, although some safety concerns have been reported. The growing care demand now and in the future urges further development of S-OPAT care" Maaskant et al (2025).
"We aimed to investigate the relationship between the total noradrenaline dose administered via PIVCs and the development of phlebitis by considering the influence of noradrenaline as a time-dependent covariate” Yasuda et al (2025).
"Post-procedure chest X-ray to confirm this access indicated that this central venous catheter (CVC) was misplaced, with its tip placed into the right axillary vein" Arif et al (2025).
"OPAT appears to be safe and effective for IE patients, with low mortality and relapse rates. However, increased readmission rates and IV-line complications warrant careful patient selection and monitoring. Further prospective trials are needed to refine OPAT protocols" Ashraf et al (2025).
"These datasets might be useful as additional support while performing femoral vein cannulation in complicated and challenging cases where the facility of radiological monitoring is not available" Ghosh et al (2025).
"To investigate whether tissue adhesive (TA, 2-octyl blended with n-butyl cyanoacrylate) application to centrally/femorally inserted central catheters (CICCs/FICCs) exit sites could reduce the occurrence of central line-associated bloodstream infection (CLABSI)” Kwon et al (2025).
"This QIP has successfully reduced early phlebitis rate in this patient population to 2.1%, which is now in-keeping with CDC guidance of <5%. In addition, there was a 65.5% improvement in documentation of VIP score demonstrating increased application of the tool in clinical practice” O’Donnell et al (2024).
"To verify the effectiveness of AccuVeinAV300® in the success of peripheral intravenous catheterization in adults with difficult intravenous access, compared to the traditional clinical method" Bittencourt et al (2025).
"A taskforce was convened to plan, develop and implement hospital-wide, evidence-based practice approaches, aligned with clinical care standards, to reduce the incidence of PIVC related infection" Sammut et al (2025).
